Stock Watch: Poxel Passes Go…But To Where?
Japanese Approval Is No Guarantee Of Commercial Success
Executive Summary
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
You may also be interested in...
Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study
A version of the diabetes drug intended to reduce PPAR gamma activation shows hoped for benefits and safety in a Phase II study. Poxel will now choose to advance one of two mid-stage NASH candidates.
Poxel/Sumitomo's Novel Diabetes Therapy Imeglimin Nears Japan Market
Poxel’s potential first-in-class diabetes therapy, imeglimin, could be approved in Japan this year, and a new partner is being sought for the EU and US – events that would transform the outlook for the decade-old Merck Serono spin-out.
Stock Watch: The Rise Of Biotech Platforms
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.